Research
Hormonal
Peripheral administration of PYY3-36 reduces food intake and body weight gain in both lean and obese human subjects by acting on hypothalamic Y2 receptors, with sensitivity preserved in obesity unlike leptin.
Obesity does not necessarily mean you are blind to all satiety signals. Research indicates that the hormone PYY, which signals fullness, still works effectively in obese individuals, unlike leptin. This suggests that therapies targeting the PYY pathway may be effective for weight management in obesity.
GoodSupportsHIGH confidence
In both lean and obese human subjects, intravenous administration of PYY3-36 reduces appetite and food intake... this data suggests that the physiological effect of PYY is to suppress food intake... unlike leptin, the sensitivity of subjects to PYY is preserved in obese subjects.
Why this rating
The paper cites multiple human studies showing reduced food intake, though it notes some conflicting animal studies.
Source
Obesity and Appetite Control
Keisuke Suzuki et al. · Experimental Diabetes Research · 2012
DOI 10.1155/2012/824305
narrative_reviewCited 226×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., exenatide, liraglutide) reduce food intake and body weight in humans, but their use is limited by side effects like nausea and potential long-term risks.Good
- Ghrelin is the only known orexigenic gut hormone, and its levels are inversely correlated with body mass index, with obese subjects showing a less marked drop in plasma ghrelin after meal ingestion.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →